Recombinant humanized monoclonal antibody MIL162

重组人源化单克隆抗体MIL162

Report date: 2023/01/07 18:44:04

Base Information

Drug NameRecombinant humanized monoclonal antibody MIL162
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsGlomerulonephritis, Membranous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsGlomerulonephritis, Membranous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A